Medicare Enrolled
Dr. Daragh Heitzman, M.D.
Neurology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Heitzman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Heitzman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Heitzman
Dr. Daragh Heitzman is a neurology specialist in Dallas, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Heitzman performed 13,243 Medicare services across 797 unique beneficiaries.
Between the years covered by Open Payments, Dr. Heitzman received a total of $32,842 from 70 pharmaceutical and/or device companies across 817 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Heitzman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 7% volume in TX
$32,842 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,243
Medicare services
Top 7% in TX for neurology
797
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~662 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| MRI contrast dye injection (gadoterate) Administration of gadoterate meglumine, a contrast agent, in a 0.1 ml dose. |
12,080 | $0 | $1 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
419 | $124 | $440 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
107 | $18 | $85 |
| Electromyography of arm or leg muscles A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them. |
100 | $77 | $104 |
| New patient office visit, complex (60-74 min) | 81 | $157 | $626 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 52 | $62 | $165 |
| MRI of brain with and without contrast An MRI scan of the brain using contrast dye both before and after administration to provide detailed images of brain structures. |
51 | $166 | $1,530 |
| Limited needle EMG of arm or leg muscles A test that measures the electrical activity in specific muscles of the arm or leg using a needle electrode. This limited study evaluates muscle function in a targeted area. |
50 | $50 | $67 |
| Chemical nerve block for neck muscles Injection of a chemical agent to paralyze specific muscles on the side of the neck, excluding the voice box. |
48 | $160 | $580 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
42 | $25 | $100 |
| Nerve conduction studies, 11-12 A diagnostic test that measures how well nerves send electrical signals. It involves performing 11 to 12 separate nerve conduction studies. |
41 | $191 | $800 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
39 | $94 | $355 |
| Needle electromyography of trunk or head muscles A test that uses a needle electrode to measure the electrical activity of muscles in the trunk or head. This helps evaluate muscle and nerve function. |
28 | $65 | $96 |
| MRI of head blood vessels without contrast An MRI scan that creates detailed images of the blood vessels in the head without using contrast dye. |
20 | $85 | $1,225 |
| Nerve conduction studies, 13 or more A diagnostic test that measures how well nerves send electrical signals. This code applies when 13 or more individual nerve studies are performed. |
19 | $223 | $915 |
| MRI of lower spine, without contrast A magnetic resonance imaging scan of the lower spinal canal that does not use contrast dye to create detailed images of the spine. |
15 | $90 | $990 |
| Awake and drowsy EEG A test that records electrical activity in the brain while the patient is awake and drowsy. |
15 | $306 | $1,110 |
| MRI of neck blood vessels with and without contrast This procedure uses magnetic resonance imaging to create detailed pictures of the blood vessels in the neck. Images are taken both before and after the administration of a contrast dye to enhance visibility. |
13 | $222 | $1,930 |
| MRI of upper spine without contrast An MRI scan of the upper spinal canal that does not use contrast dye. This imaging test uses magnetic fields and radio waves to create detailed pictures of the spine. |
12 | $65 | $975 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
11 | $72 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$32,842
Total received (2018-2024)
Avg $4,692/year across 7 years
Top 12% in TX for neurology
70
Companies
817
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$15,419 (46.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,849 (42.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,575 (10.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,443
2023
$12,324
2022
$3,604
2021
$3,721
2020
$641
2019
$1,932
2018
$7,177
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amylyx Pharmaceuticals, Inc.
$10,337
Merz North America, Inc.
$5,042
MITSUBISHI TANABE PHARMA AMERICA, INC.
$3,575
Genentech USA, Inc.
$963
UCB, Inc.
$813
Sunovion Pharmaceuticals Inc.
$788
Biogen, Inc.
$761
ABBVIE INC.
$716
Alexion Pharmaceuticals, Inc.
$702
GENZYME CORPORATION
$550
Allergan Inc.
$517
Novartis Pharmaceuticals Corporation
$516
Teva Pharmaceuticals USA, Inc.
$506
ARGENX US, INC.
$492
PFIZER INC.
$466
Lilly USA, LLC
$384
Avanir Pharmaceuticals, Inc.
$355
Celgene Corporation
$322
Merz Pharmaceuticals, LLC
$297
Janssen Pharmaceuticals, Inc
$285
Amgen Inc.
$272
ACADIA Pharmaceuticals Inc
$257
Lundbeck LLC
$255
Eisai Inc.
$237
Neurocrine Biosciences, Inc.
$236
EMD Serono, Inc.
$224
Takeda Pharmaceuticals U.S.A., Inc.
$219
Ipsen Biopharmaceuticals, Inc
$209
McKesson Specialty Care Distribution, LLC
$203
SK Life Science, Inc.
$170
Acorda Therapeutics, Inc
$161
AbbVie Inc.
$150
Allergan, Inc.
$134
Amneal Pharmaceuticals LLC
$130
Biohaven Pharmaceuticals, Inc.
$114
Grifols USA, LLC
$109
Biohaven Pharmaceutical Holding Company Ltd.
$107
Mitsubishi Tanabe Pharma America, Inc.
$99
Upsher-Smith Laboratories LLC
$86
Horizon Therapeutics plc
$85
CSL Behring
$81
Avion Pharmaceuticals
$66
Adamas Pharmaceuticals, Inc.
$61
Alnylam Pharmaceuticals Inc.
$61
Bayer HealthCare Pharmaceuticals Inc.
$55
TG Therapeutics, Inc.
$53
AbbVie, Inc.
$50
Corium, LLC
$49
CATALYST PHARMACEUTICALS, INC.
$41
Neurelis, Inc.
$39
Avadel CNS Pharmaceuticals, LLC
$34
TG THERAPEUTICS, INC.
$32
Mallinckrodt LLC
$32
Otsuka America Pharmaceutical, Inc.
$32
UPSHER-SMITH LABORATORIES LLC
$31
Tactile Systems Technology Inc
$29
Greenwich Biosciences, Inc.
$28
Kyowa Kirin, Inc.
$27
Harmony Biosciences Llc
$24
Octapharma USA, Inc.
$21
Boston Scientific Corporation
$19
Philips Electronics North America Corporation
$18
Medtronic USA, Inc.
$17
Assertio Therapeutics, Inc.
$17
BOSTON SCIENTIFIC CORPORATION
$15
GE HEALTHCARE
$15
IDORSIA PHARMACEUTICALS US INC
$14
Catalyst Pharmaceuticals, Inc.
$13
HOSPIRA, INC.
$13
HARMONY BIOSCIENCES LLC
$13
Top 3 companies account for 57.7% of total payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMPYRA · AMYVID · APTIOM · AUBAGIO · AUSTEDO · Adlarity · Aimovig · Austedo XR · BOTOX · BOTOX THERAPEUTIC · BRIUMVI · Betaseron · Briviact · CAMBIA · COMIRNATY · COPAXONE · DAYBUE · DUOPA · DYSPORT · Dhivy · Duopa · Dysport · EMGALITY · Enspryng · Epidiolex · Evrysdi · FABRY-DISEASE · FIRDAPSE · Flexitouch Plus · Fycompa · GAMMAGARD · GILENYA · GOCOVRI · Gamunex-C · HYQVIA · Hizentra · INBRIJA · INGREZZA · KESIMPTA · KYNMOBI · LEADPOINT · LEMTRADA · LUMIZYME · LUMRYZ · LYRICA · Leqembi · MAYZENT · Mavenclad · NEXVIAZYME · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Nuedexta · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONGENTYS · ONPATTRO · Ocrevus · Ongentys · PANZYGA · PAXLOVID · POMPE - DISEASE · Ponvory · QUDEXY XR TOPIRAMATE EXTENDED RELEASE CAPSULES · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · QUVIVIQ · RADICAVA · RELYVRIO · REXULTI · RYTARY · Radicava · Rebif · Rystiggo · SOLIRIS · Skyclarys · Soliris · TECFIDERA · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TYSABRI · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VERCISE · VRAYLAR · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vercise · Vimpat · WAKIX · Wakix · XEOMIN · Xeomin · ZEPOSIA · Zinbryta · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (47%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $248 per 100 Medicare services performed
Geographic Context
Neurologists within 10 mi
241
Per 100K population
9.3
County median income
$74,149
Nearest hospital
BAYLOR SCOTT AND WHITE MEDICAL CENTER UPTOWN
2.3 mi
2.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Heitzman is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), with speaking/promotional industry engagement in the top 12% of TX peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Heitzman experienced with mri contrast dye injection (gadoterate)?
Based on Medicare claims data, Dr. Heitzman performed 12,080 mri contrast dye injection (gadoterate) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Heitzman receive payments from pharmaceutical companies?
Yes. Dr. Heitzman received a total of $32,842 from 70 companies across 817 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Heitzman's costs compare to other neurologists in Dallas?
Dr. Heitzman's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Heitzman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Dallas
Browse neurologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in TX
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in TX
Which TX neurologists receive the most from drug and device companies.
By company
Amylyx Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Amylyx Pharmaceuticals, Inc.
By company
Merz North America, Inc. Payments to Doctors
See all physicians who received payments from Merz North America, Inc.
By company
MITSUBISHI TANABE PHARMA AMERICA, INC. Payments to Doctors
See all physicians who received payments from MITSUBISHI TANABE PHARMA AMERICA, INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology